AXTA vs ICL

AXTA's deterministic scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades below the growth-based intrinsic value of $48.10 but above the conservative Graham Number of $22.25, suggesting mixed valuation signals. Despite solid profitability metrics like a 21.33% ROE and consistent earnings beats, revenue is contracting YoY by 2.40%, and insider activity is bearish with recent selling. Analysts recommend a 'buy' with a $36.71 target, implying moderate upside from current levels around $33.62.

ICL presents a precarious profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant valuation gap, with the current price ($5.54) trading well above both the Graham Number ($4.33) and the Intrinsic Value ($1.26). While the balance sheet is healthy with low debt (D/E 0.44), the company suffers from razor-thin profit margins (3.16%) and a highly unsustainable dividend payout ratio of 96.39%. Technicals are overwhelmingly bearish (0/100), and the stock has seen a 16.4% decline over the past year, suggesting a lack of market confidence despite a 'hold' analyst consensus.